Voleon Capital Management LP Sells 34,020 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Voleon Capital Management LP sold 34,020 shares of Gilead Sciences, reducing its holdings by 60.4%, leaving it with 22,334 shares valued at approximately $2.5 million.
• Insider Johanna Mercier sold 28,000 shares for over $3.3 million, marking a 19.7% decrease in her position, while CFO Andrew D. Dickinson also sold shares worth $296,325.
• Gilead Sciences recently announced a quarterly dividend of $0.79 per share, with a yield of 2.7%, and has an average analyst rating of "Moderate Buy" with a consensus price target of $115.39.

Voleon Capital Management LP decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 60.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,334 shares of the biopharmaceutical company's stock after selling 34,020 shares during the period. Voleon Capital Management LP's holdings in Gilead Sciences were worth $2,503,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth approximately $25,000. Activest Wealth Management increased its holdings in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 227 shares in the last quarter. Goodman Advisory Group LLC acquired a new stake in shares of Gilead Sciences during the first quarter worth approximately $29,000. Colonial Trust Advisors lifted its position in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 213 shares in the last quarter. Finally, Core Alternative Capital lifted its position in Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 241 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the sale, the director directly owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider directly owned 114,168 shares of the company's stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 82,000 shares of company stock valued at $9,371,330. Insiders own 0.27% of the company's stock.

Gilead Sciences Trading Down 2.8%

Shares of GILD stock traded down $3.31 on Friday, reaching $114.55. The company had a trading volume of 6,466,956 shares, compared to its average volume of 5,830,447. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market cap of $142.13 billion, a PE ratio of 22.82, a PEG ratio of 0.80 and a beta of 0.36. The company has a 50-day moving average of $114.04 and a 200-day moving average of $110.09. Gilead Sciences, Inc. has a 12 month low of $81.57 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio is 62.95%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on GILD. Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. UBS Group upped their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and upped their target price for the company from $108.00 to $127.00 in a research report on Friday, August 8th. Dbs Bank upgraded shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Finally, Daiwa Capital Markets upgraded shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a research report on Tuesday, August 19th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $115.39.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.